<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F93F6C72-B2CD-4D45-ADE1-581F814EA0BD"><gtr:id>F93F6C72-B2CD-4D45-ADE1-581F814EA0BD</gtr:id><gtr:name>Cancer Research Technology (CRT)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F93F6C72-B2CD-4D45-ADE1-581F814EA0BD"><gtr:id>F93F6C72-B2CD-4D45-ADE1-581F814EA0BD</gtr:id><gtr:name>Cancer Research Technology (CRT)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/AF2BADC5-2F67-4EC8-94C1-33649FE9F4D6"><gtr:id>AF2BADC5-2F67-4EC8-94C1-33649FE9F4D6</gtr:id><gtr:firstName>W Gillies</gtr:firstName><gtr:surname>McKenna</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12004"><gtr:id>8C630E3F-AE63-4784-8634-8664A99A01A6</gtr:id><gtr:title>Molecular determinants of Radiosensitivity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12004</gtr:grantReference><gtr:abstractText>Radiation remains second only to surgery in curing cancer, but there is wide variation from patient to patient is the effectiveness of radiation treatment. Some of this is due to the fact that some cancers are much more sensitive to radiation treatment than others. We aim to try to discover what causes this difference in effectiveness to see whether we could find drugs that could be used with radiation to make the cancers more sensitive to treatment. If successful this could increase our chance of curing the cancer and might even allow us to use lower doses of radiation to achieve the maximum effect.</gtr:abstractText><gtr:technicalSummary>Significant gains in the therapeutic ratio of radiotherapy could be made if treatments could be developed that selectively rendered tumour cells specifically more sensitive to IR without altering the sensitivity of normal tissues. We plan to identify clinically exploitable targets that may enable tumours to be made more sensitive to radiotherapy using siRNA screens.
We will screen a druggable genome library using HeLa cells, and a library of 800 kinase genes using NSCLC cell lines containing specific mutations. The aim is to identify novel genes whose depletion induces tumour-specific radiosensitisation. The clinical significance of those genes confirmed as being involved in tumour cell radioresistance will be assessed by correlating the clinical outcomes of retrospective series of cancer patients with the tumour RNA expression levels of these genes.
We will also continue to investigate the mechanism of action of a gene (POLQ) that we have recently been shown to be involved in tumour cell radiosensitivity. We have previously shown that tumour cells depleted of POLQ are rendered more sensitive to ionising radiation and chemotherapy as a result of reduced homologous recombination efficiency. The structural basis for this will be examined using truncated POLQ constructs to determine which parts of POLQ are involved in altering radiosensitivity. This may enable us to identify which parts of POLQ could be targeted pharmacologically to inhibit POLQ.

The future plans also focus on understanding the mechanisms that lead to vascular normalisation and decreased hypoxia in tumours after PI3K/mTOR inhibtition and determining whether these events occur in human tumours. We propose two approaches. 

We will evaluate the time course of changes in hypoxia and perfusion after inhibitor treatment. We know that approximately 75% of the improvement in perfusion and oxygenation has occurred by 72h. We will now evaluate the changes at earlier times along with evaluation of drug efficacy based on IHC at these times. We will also determine the reversibility of the events after drug withdrawal. Knowing the timing of the changes will allow us to determine whether alterations in vascular morphology for example precede or follow changes in oxygenation. 

We will determine whether the increased oxygen level after inhibition of PI3K might be due to decreased oxygen consumption using tissue culture and spheroid models. At the same time we will measure ATP levels, lactate and pH after drug treatment. If there are detectable shifts we will also measure other key metabolites.</gtr:technicalSummary><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>3214000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research Technology (CRT)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Cancer drug discovery</gtr:description><gtr:id>A45BD941-B6ED-4B23-8B4B-D20801CAD9DD</gtr:id><gtr:impact>No academic output yet</gtr:impact><gtr:outcomeId>56d8246e696bc1.03421783-1</gtr:outcomeId><gtr:partnerContribution>Development of chemical inhibitors. With the support of the team in Oxford CRT have obtained a commercial partner for future work.</gtr:partnerContribution><gtr:piContribution>Identification of a clinically exploitable drug target (POLQ). We are now collaborating on the preclinical testing of lead compounds.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>The generation of novel mitochondrial complex 1 inhibitors that relieve tumour hypoxia</gtr:description><gtr:id>AE22B16B-A931-4A6F-B645-F94516131D4D</gtr:id><gtr:impact>Initial test compounds were tested for their ability to reduce oxygen consumption. Two compounds of interest were identified and will be further modified by the Chemistry lab (Chris Schofield).
Disciplines: Radiation Oncology (McKenna) and Chemistry (Schofield).
Three sets of comp`ounds have now been generated and tested for their potential to reduce the OCR, with several promising compounds identified.</gtr:impact><gtr:outcomeId>56d8270ac19de0.35701082-1</gtr:outcomeId><gtr:partnerContribution>See above</gtr:partnerContribution><gtr:piContribution>Our lab will perform three experiments to evaluate complex 1 inhibitory fenofibrate derivatives generated by the Chemistry lab.
1) Do compounds reduce the oxygen consumption rate of cancer cells?
ii) Do the compounds alleviate spheroid hypoxia?
iii) Do the compounds alleviate tumour hypoxia?</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Proton NHS event</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>F61C61B8-BAEA-4E5D-BAB4-768155CA5421</gtr:id><gtr:impact>This was an event to inform clinicians at the Oxford University Hospitals NHS Trust about the Precision Cancer Medicine Institute</gtr:impact><gtr:outcomeId>56d857d7f2dc74.40513707</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC radio interview on the Today programme</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>763532A5-6BE8-49E3-A097-C123BEFA8218</gtr:id><gtr:impact>Interview on the Today programme</gtr:impact><gtr:outcomeId>56d8542da6fa94.95281463</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presenting at local MPs Labour Party meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>950ED73D-57FE-4B6F-84CB-3FA51F8968C2</gtr:id><gtr:impact>Talk was very well received and sparked interest</gtr:impact><gtr:outcomeId>56d85691bb7133.82168682</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The future of targeted cancer therapy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F36CA88F-DD20-4794-A0D0-36F743FE3FBB</gtr:id><gtr:impact>5th &amp;amp; 6th July 2013
Plenary lecture

presentation followed by discussion</gtr:impact><gtr:outcomeId>rUH3uF4ZWCJ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.uni-due.de/imperia/md/content/medizin/de/studium/retreat_2013_grk_1739.pdf</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK filming</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>41CEF15E-53B2-40FE-8009-95B4675FE4DF</gtr:id><gtr:impact>Taking part in a short documentary film for CRUK to present to members o the public to assist with fundraising

due to be released December 2013</gtr:impact><gtr:outcomeId>kbHbxmCFT71</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Two new cancer research centres to open in Oxford</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>93EDBD0F-B70B-4BED-B00B-42DF764D53D2</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>oEhHwANixgJ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Professor McKenna - BBC Radio 4 Interview with Paddy O'Connell</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0DFE2C3D-4341-4DF8-B619-C0B00AFF2186</gtr:id><gtr:impact>The interview created increased interest

N/A</gtr:impact><gtr:outcomeId>545df62459bf57.36984873</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof Gillies McKenna to head new world-leading cancer research centre</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>BAC48893-7260-44EB-BF04-701DAB270806</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>JcB8uuQVCWa</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Current limitations of radiotherapy imaging and the future role of functional imaging</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E8074E54-6889-4C5E-8814-A5AB053DCAD9</gtr:id><gtr:impact>presenting at Oncology RCR Annual meeting

presentation followed by discussion session</gtr:impact><gtr:outcomeId>qKwmUsnm1fA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.rcr.ac.uk/docs/oncology/pdf/Onc_AnnualMeeting.pdf</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alpha radiation treats prostate cancers</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FFA58BE2-65AD-4477-A9D7-A503C0800355</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>shT61Zyo4TV</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Major Donor Visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>455AC24F-7E78-44EE-8D19-7AAA33DCCD45</gtr:id><gtr:impact>Sept 2013, presentation to existing major donor

On going discussions for potential funding</gtr:impact><gtr:outcomeId>kuahCCZ3uZS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Why do we still use radiation to treat cancer?</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>A9F0E240-AA73-4B51-BCFC-B7AFA020F2FD</gtr:id><gtr:impact>24 June 13 invited seminar speaker, then hosted to meet other academics in Glasgow

formed new contacts</gtr:impact><gtr:outcomeId>QnaKQNqaMxQ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New Prostate cancer treatment may reduce side effects</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>37D8CCE5-53C2-4DF5-A887-FB16A0C7EE63</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>eZGUrjitHK5</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Major Donor Visit hosted by Professor McKenna and others</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A833321E-1313-4C94-A6D1-857AAAEFD794</gtr:id><gtr:impact>Major donor visit hosted with other key scientists and clinicians

This visit helped inform the donor</gtr:impact><gtr:outcomeId>545df56c1800b8.35990298</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mirada Medical excites AAPM with latest additions to RTxSoftware</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DA427EEC-27E5-47D2-94F3-5ED7E3C06031</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>KzeMGCZ71Fk</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Is spending on proton beam therapy for cancer going too far too fast?</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>44C0AD89-7A9F-4F44-B89C-FE37299CFEE4</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>hu3HX2G7uQQ</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alpha particles used to trear prostate cancer that has spread to bone</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4A60E7FB-FBE6-4888-A380-BC08042E20BD</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>GL7Fsbbebpe</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>The Tumour Microenvironment in Radiotherapy. Approaches to the Problem</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>92C0595F-4061-4187-84B1-5F11F950D13B</gtr:id><gtr:impact>multidisciplinary symposium entitled &amp;quot;New Cancer Targets (NCT) on September 23-24th, 2013, in Heidelberg. Germany.


presentation and discussion</gtr:impact><gtr:outcomeId>Yeeg4HwFJhc</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://www.google.co.uk/url?sa=t&amp;rct=j&amp;q=&amp;esrc=s&amp;source=web&amp;cd=107&amp;ved=0CEgQFjAGOGQ&amp;url=http%3A%2F%2Fwww.kinderkrebsinfo.de%2Fe2331%2Fe5225%2Fitems%2F%40273%2FNCTConference2013_Flyer_eng.pdf&amp;ei=6NVbUv_SE-Wm0AXfh4GABw&amp;usg=AFQjCNEF7FKahidT6ilytPNIPOslyfDHtA</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Cancer victims welcome ?138m research centre</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>FD7CF3B3-B60D-459B-9A03-3D3B78171591</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>RdCbwSD82sM</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Centre will see city lead the world in cancer care</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>236B89AE-CA21-4BC2-9347-88950702BD10</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>UmdzbCDvwfG</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Professor McKenna presenting the David Skeggs Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>02A7B47A-3958-4575-B7CD-58CA0DD79D64</gtr:id><gtr:impact>Talk sparked questions and discussion afterwards

Acknowledgement of work</gtr:impact><gtr:outcomeId>545df84cb112f3.00502783</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC radio interview on the Today programme</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3BF7A187-461A-4AD7-BF5D-F5C022E0B945</gtr:id><gtr:impact>October 2013, Interview with Tom Feilden, science correspondent for the Today programme

heard by anyone listening to the Today programme on BBC radio 2</gtr:impact><gtr:outcomeId>ZceYuQkmYFF</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Professor McKenna's talk to Department of Oncology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8A0CD335-C0B7-493D-9A6C-694BABCA3F0D</gtr:id><gtr:impact>The talk created more interest

N/A</gtr:impact><gtr:outcomeId>545df69773dec1.03996709</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Article in Oxford Mail</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1EEAD01A-66CF-4AB9-BE39-9A78B02C8F54</gtr:id><gtr:impact>Group of scientists bringing science to the public
Monthly meeting

The members of the public who attended are now more aware of the areas of science that were discussed.</gtr:impact><gtr:outcomeId>Abshpq3gf5o</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press launch for Precision Cancer Medicine Institute</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A5E13E36-D0B0-45AC-BE2E-9D7F37C18DF6</gtr:id><gtr:impact>Local BBC TV, Local BBC Radio, Jack FM, Oxford Mail

The press launch resulted in many enquiries</gtr:impact><gtr:outcomeId>545df71c414b85.57438137</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MP visit to Professor McKenna</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>0F0C424A-F4DC-49DA-B9F7-6D210B3D75C1</gtr:id><gtr:impact>N/A

The visit updated the MP about the activities in the Department of Oncology</gtr:impact><gtr:outcomeId>545dfc90bf5ef0.61380638</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Prof Gillies McKenna giving the Frank Ellis Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E725456A-28BE-4F3D-A0D1-04E56A2C8D1F</gtr:id><gtr:impact>on line presentation open to everyone on the www

Open to all</gtr:impact><gtr:outcomeId>a3XJf4GcMEa</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:url>http://twitter.com/RCRadiologists/status/339734619660374017</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>New techniques and personalised treatment in Radiotherapy</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>CA225A73-F531-4438-869D-37DBF88C4520</gtr:id><gtr:impact>N/A</gtr:impact><gtr:outcomeId>bhheiBSE9jj</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Major Donor visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>207074D9-AA4D-4D01-AC3B-B2BD11521EFF</gtr:id><gtr:impact>January 2013 Major Donor visit, hosted together with other key scientists and clinicians

Interaction with potential high level donors</gtr:impact><gtr:outcomeId>bnUz8oxXW6m</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>390060</gtr:amountPounds><gtr:country>Japan</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Application for support to create a precision medicine research team to undertake translational and clinical research to improve treatment for pancreatic cancer</gtr:description><gtr:end>2017-06-02</gtr:end><gtr:fundingOrg>Kidani Memorial Trust</gtr:fundingOrg><gtr:id>1025F580-53B1-4195-8E49-DB5441CDC999</gtr:id><gtr:outcomeId>56dea7fb4abb27.75316172</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Equipment allocation</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C5255/A12331</gtr:fundingRef><gtr:id>9DB33123-8F6A-4114-920E-8C5AE21AF9AA</gtr:id><gtr:outcomeId>DqTcG3e1qn2</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>563390</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Early Phase Oncology Trial Infrastructure</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Oxford University Hospitals NHS Foundation Trust</gtr:fundingOrg><gtr:fundingRef>ONC1516/01</gtr:fundingRef><gtr:id>50131C18-BE69-43ED-AC38-74F436CDE516</gtr:id><gtr:outcomeId>56dea69a82db91.73771679</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>742823</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Oxford CRUK Training</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C38302/A12450</gtr:fundingRef><gtr:id>5F4E439F-43F0-443E-8930-990F86C446C4</gtr:id><gtr:outcomeId>XWTSZs1rGSs</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4081374</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Oxford CRUK (OCRC)</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:fundingRef>C38302/A12278</gtr:fundingRef><gtr:id>AFC7FE0E-33F6-4E47-B9DA-82D3A5984265</gtr:id><gtr:outcomeId>p9VbmdgomGd</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>CR-UK Research Strategy Committee</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8347AE15-CA9A-43FA-8182-30E1B0FDD0A7</gtr:id><gtr:outcomeId>hsLkA96Wfmt</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>AACR Annual Meeting Program Committee</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>E2863FF3-3A73-4DBA-9524-508A58924A2F</gtr:id><gtr:outcomeId>56d85db71b5ff9.61291690</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>International Scientific Advisory Board of Institut Curie, Paris, France</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>0B259CB3-769B-4CE3-B37D-838D61774F90</gtr:id><gtr:outcomeId>56d85d79683f99.61520158</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>AACR Colon Cancer Research Fellowships Scientific Review Committee</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>D0E81138-48CE-4286-A01A-635A4F759759</gtr:id><gtr:outcomeId>arq5WhQB5qU</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NCRI Radiotherapy Radiobiology Rapid Review Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6A193B4D-3340-4762-8DDC-89F192647A06</gtr:id><gtr:outcomeId>0BEDE11035C</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>AACR Radiation Biology Section of the Tumor Biology Subcommittee 2014</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>B8CCA777-E95C-42B2-9D5E-9D8D73600E68</gtr:id><gtr:outcomeId>T4Yw5auSYDx</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific Advisory Board of the German Cancer consortium (DKTK)</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>63925294-7B00-4505-B6A4-56638C2E3AFC</gtr:id><gtr:outcomeId>54638c1a87f410.60025307</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Institut Universaire du Cancer, Toulouse, France Scientific Advisory Board</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>CA334DF0-190C-4F85-AB12-2CAF4D5605CF</gtr:id><gtr:outcomeId>56d85c902a10f6.37063004</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Advisory role to facilitate the development of AACRs programs and initiatives related to radiation oncology</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>6F97D3DF-44F8-4C9F-9B06-98CE76D14338</gtr:id><gtr:outcomeId>56d85b19646679.38116935</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>AACR Radiation Oncology Task Force</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>955F1A98-B40A-4E0E-A69B-994AC4D5F69D</gtr:id><gtr:outcomeId>54638bd75045b9.13930650</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Chair of the Scientific Advisory Board for the University Cancer Center, Dresden, Germany</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>7496BDCC-F8EE-4E67-A13B-9218304270A2</gtr:id><gtr:outcomeId>56d85c43004472.64067949</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0234F452-1F31-4B36-93EC-CAA89065F962</gtr:id><gtr:title>The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1779925d4d04694be3a854b91f21ea91"><gtr:id>1779925d4d04694be3a854b91f21ea91</gtr:id><gtr:otherNames>Al-Assar O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>58c13d50bda834.37250391</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6B0F2630-0C60-4F7D-A60C-3B3E7F05F017</gtr:id><gtr:title>Internalization of Auger electron-emitting isotopes into cancer cells: a method for spatial distribution determination of equivalent source terms.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4ae575a7e051ac4adba2801232a26756"><gtr:id>4ae575a7e051ac4adba2801232a26756</gtr:id><gtr:otherNames>Royle G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>5a31e68150be27.80048345</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CFBD1ED-60BE-40E4-9AEF-4D4BBFF0508B</gtr:id><gtr:title>Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28fe5f88f7a44c30e3c7ac9ef42138fc"><gtr:id>28fe5f88f7a44c30e3c7ac9ef42138fc</gtr:id><gtr:otherNames>Fokas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>565585f43c74b8.60626311</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4ED781C0-B6B7-4A94-AEA3-12CDC814A7F5</gtr:id><gtr:title>Targeting telomerase with radiolabeled inhibitors.</gtr:title><gtr:parentPublicationTitle>European journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/84b1ce70968763c6cf8c3918b2fb6aa7"><gtr:id>84b1ce70968763c6cf8c3918b2fb6aa7</gtr:id><gtr:otherNames>Waghorn PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0223-5234</gtr:issn><gtr:outcomeId>5a35c9a0391b56.85536979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C502E970-4722-47F0-B359-373AC9C0E6E5</gtr:id><gtr:title>Contextual regulation of pancreatic cancer stem cell phenotype and radioresistance by pancreatic stellate cells.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1779925d4d04694be3a854b91f21ea91"><gtr:id>1779925d4d04694be3a854b91f21ea91</gtr:id><gtr:otherNames>Al-Assar O</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>545cc75181fc93.03326411</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37001DD6-15C8-4B5C-939F-6B1786ACDCD7</gtr:id><gtr:title>Dual inhibition of the PI3K/mTOR pathway increases tumor radiosensitivity by normalizing tumor vasculature.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28fe5f88f7a44c30e3c7ac9ef42138fc"><gtr:id>28fe5f88f7a44c30e3c7ac9ef42138fc</gtr:id><gtr:otherNames>Fokas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_12478_28_22108822</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC600368-9174-4DCF-9EF2-07DD432D0401</gtr:id><gtr:title>Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7a63f38520eda8608578e19eca089ace"><gtr:id>7a63f38520eda8608578e19eca089ace</gtr:id><gtr:otherNames>Qayum N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>pm_12478_28_22065081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9DBD395-3A58-4676-9DAA-15B5ED0E9E08</gtr:id><gtr:title>ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2ffd4919451824364820657fe5fa13fe"><gtr:id>2ffd4919451824364820657fe5fa13fe</gtr:id><gtr:otherNames>Wilson JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>58c13d508cc822.60514482</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5CF4887-93E2-47EA-AB74-4225BAEADF62</gtr:id><gtr:title>PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/20327a24468ecfadd7abbe7971e9bbf6"><gtr:id>20327a24468ecfadd7abbe7971e9bbf6</gtr:id><gtr:otherNames>Azad A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>58c13d51e5ce34.95542230</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>07630012-C1D6-4B2E-8BBA-9961C571A9BA</gtr:id><gtr:title>Targeted radionuclide therapy in combined-modality regimens</gtr:title><gtr:parentPublicationTitle>LANCET ONCOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d8c450d1d52f53937571a454e3033e3"><gtr:id>3d8c450d1d52f53937571a454e3033e3</gtr:id><gtr:otherNames>Gill Martin R.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>5a35cb3b2cdef9.25278989</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4847BB2-E8B9-4B34-BF38-787F3B5548F5</gtr:id><gtr:title>Corrigendum: Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate toward tumour blood vessels</gtr:title><gtr:parentPublicationTitle>Nature Communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3048ba303c2ab5fdae5fc871b9112d3"><gtr:id>e3048ba303c2ab5fdae5fc871b9112d3</gtr:id><gtr:otherNames>Harada H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>pm_12478_28_24129309</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A9517F9-F385-405C-9EF7-AEFBDBE96DCB</gtr:id><gtr:title>Depletion of signal recognition particle 72kDa increases radiosensitivity.</gtr:title><gtr:parentPublicationTitle>Cancer biology &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/574aa5fbcc2eb8c8e59f4f4bda22d5c5"><gtr:id>574aa5fbcc2eb8c8e59f4f4bda22d5c5</gtr:id><gtr:otherNames>Prevo R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1538-4047</gtr:issn><gtr:outcomeId>5aa7b3d5b223e6.89317442</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>21494966-47FD-4447-ABE7-266A38152B98</gtr:id><gtr:title>F-fluoromisonidazole uptake in advanced stage non-small cell lung cancer: A voxel-by-voxel PET kinetics study.</gtr:title><gtr:parentPublicationTitle>Medical physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e7d98f0f80925457a83e2aa2e543159"><gtr:id>0e7d98f0f80925457a83e2aa2e543159</gtr:id><gtr:otherNames>McGowan DR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0094-2405</gtr:issn><gtr:outcomeId>5aa7b2ecf0e4e1.30480799</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7547283-9B95-409C-9251-F90D5B2AC2C1</gtr:id><gtr:title>Targeting ATR in DNA damage response and cancer therapeutics.</gtr:title><gtr:parentPublicationTitle>Cancer treatment reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28fe5f88f7a44c30e3c7ac9ef42138fc"><gtr:id>28fe5f88f7a44c30e3c7ac9ef42138fc</gtr:id><gtr:otherNames>Fokas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7372</gtr:issn><gtr:outcomeId>pm_12478_28_23583268</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69A0A0CE-A486-4083-ACAE-60FF86EB6085</gtr:id><gtr:title>Dilemmas concerning dose distribution and the influence of relative biological effect in proton beam therapy of medulloblastoma.</gtr:title><gtr:parentPublicationTitle>The British journal of radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/02a692102c18c95a1f2217f9c024bb0c"><gtr:id>02a692102c18c95a1f2217f9c024bb0c</gtr:id><gtr:otherNames>Jones B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1285</gtr:issn><gtr:outcomeId>545de4e2e1dde6.14387501</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26B47212-58FB-4255-B629-76C2FA9F2B86</gtr:id><gtr:title>Identification of vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/febf45dc246d13982d529fce977cc2ee"><gtr:id>febf45dc246d13982d529fce977cc2ee</gtr:id><gtr:otherNames>Tiwana GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>565586936c4e52.05747517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3619B27B-5944-4F49-8411-CF24B38E6930</gtr:id><gtr:title>TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/722bec08d1ae0b6ca0835b0496f2c666"><gtr:id>722bec08d1ae0b6ca0835b0496f2c666</gtr:id><gtr:otherNames>Pirovano G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>5aa7b2915ece56.84003629</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A3EFA59-76C1-4790-975D-7096DAE5C2C5</gtr:id><gtr:title>Improved outcome ofI-mIBG treatment through combination with external beam radiotherapy in the SK-N-SH mouse model of neuroblastoma.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/18f56c29e7373e99e630b80c866be8f8"><gtr:id>18f56c29e7373e99e630b80c866be8f8</gtr:id><gtr:otherNames>Corroyer-Dulmont A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>5a35cd9ee08a33.30638933</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90BE9C53-2D5A-47C7-8994-9A5DC22EAD0A</gtr:id><gtr:title>A treatment planning comparison of four target volume contouring guidelines for locally advanced pancreatic cancer radiotherapy.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28fe5f88f7a44c30e3c7ac9ef42138fc"><gtr:id>28fe5f88f7a44c30e3c7ac9ef42138fc</gtr:id><gtr:otherNames>Fokas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>pm_12478_28_23647755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8175590A-BB8B-4CED-859D-0351D2CB69D0</gtr:id><gtr:title>Homologous recombination mediates S-phase-dependent radioresistance in cells deficient in DNA polymerase eta.</gtr:title><gtr:parentPublicationTitle>Carcinogenesis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f3c32ad0537b5e13b0549aff3edceda"><gtr:id>1f3c32ad0537b5e13b0549aff3edceda</gtr:id><gtr:otherNames>Nicolay NH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0143-3334</gtr:issn><gtr:outcomeId>pm_12478_28_22822095</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FD0DB9A6-C438-438C-8E0B-3D98FA6F1E59</gtr:id><gtr:title>Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e3048ba303c2ab5fdae5fc871b9112d3"><gtr:id>e3048ba303c2ab5fdae5fc871b9112d3</gtr:id><gtr:otherNames>Harada H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>pm_12478_28_22510688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>482DA7BC-9D00-4325-A941-24EECBD51D17</gtr:id><gtr:title>The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.</gtr:title><gtr:parentPublicationTitle>Cancer metastasis reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28fe5f88f7a44c30e3c7ac9ef42138fc"><gtr:id>28fe5f88f7a44c30e3c7ac9ef42138fc</gtr:id><gtr:otherNames>Fokas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0167-7659</gtr:issn><gtr:outcomeId>pm_12478_28_22825313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>518859DB-1C6C-4D7B-920E-CDDC052BD227</gtr:id><gtr:title>Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors.</gtr:title><gtr:parentPublicationTitle>Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b510af5c8675372b5bf45633694ef94"><gtr:id>9b510af5c8675372b5bf45633694ef94</gtr:id><gtr:otherNames>Higgins GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0080-0015</gtr:issn><gtr:outcomeId>58c13d50e692d3.54308665</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB42F743-75EB-4074-96D7-B7F22FF653B3</gtr:id><gtr:title>An efficient and robust MRI-guided radiotherapy planning approach for targeting abdominal organs and tumours in the mouse.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a3da5c4061b4b9a0dbeae2fc6344f3cd"><gtr:id>a3da5c4061b4b9a0dbeae2fc6344f3cd</gtr:id><gtr:otherNames>Kersemans V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5a2fd764109274.48829126</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1270D6D-3552-4A8B-8604-E3A6CB906D19</gtr:id><gtr:title>NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity.</gtr:title><gtr:parentPublicationTitle>Radiation oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28fe5f88f7a44c30e3c7ac9ef42138fc"><gtr:id>28fe5f88f7a44c30e3c7ac9ef42138fc</gtr:id><gtr:otherNames>Fokas E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1748-717X</gtr:issn><gtr:outcomeId>pm_12478_28_22452803</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F8D9EF69-5CE2-48DC-BDED-11196EC05995</gtr:id><gtr:title>Targeting radiation-resistant hypoxic tumour cells through ATR inhibition.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8aeac6a20456e012f168ee0205a7a473"><gtr:id>8aeac6a20456e012f168ee0205a7a473</gtr:id><gtr:otherNames>Pires IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_12478_28_22713662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6316BCB1-327C-403A-A674-614F0E44E9A7</gtr:id><gtr:title>The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cfa77bc204b659c195f2d16a721b945"><gtr:id>5cfa77bc204b659c195f2d16a721b945</gtr:id><gtr:otherNames>Ashton TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58c13d515bbf03.69689284</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99971F38-37F1-45BF-BBD0-7EA4F3BDFDA8</gtr:id><gtr:title>Absorbed dose evaluation of Auger electron-emitting radionuclides: impact of input decay spectra on dose point kernels and S-values.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57211aa66774a9287dec3e1a588d4212"><gtr:id>57211aa66774a9287dec3e1a588d4212</gtr:id><gtr:otherNames>Falzone N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>5a2fd5b0e3c614.66907682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37BD836C-93F0-429B-8D14-F63E6A470963</gtr:id><gtr:title>Oxidative phosphorylation as an emerging target in cancer therapy.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5cfa77bc204b659c195f2d16a721b945"><gtr:id>5cfa77bc204b659c195f2d16a721b945</gtr:id><gtr:otherNames>Ashton TM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>5a995ed1c2dc27.74702152</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06B8B541-7849-48D8-B582-50A4ED09AC66</gtr:id><gtr:title>Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/165d8df9cea0c9f13b159f8c91b2343b"><gtr:id>165d8df9cea0c9f13b159f8c91b2343b</gtr:id><gtr:otherNames>Diana A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58c13d51bb7261.79623784</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3543F3F-87E8-472C-81B4-6F155D180D7D</gtr:id><gtr:title>Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/165d8df9cea0c9f13b159f8c91b2343b"><gtr:id>165d8df9cea0c9f13b159f8c91b2343b</gtr:id><gtr:otherNames>Diana A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>58c13d5120c021.17692916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>527659ED-2083-4FB3-A812-C0FE67BDC2CF</gtr:id><gtr:title>The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/33be1b0204c3408651b7bb7508b7f0fb"><gtr:id>33be1b0204c3408651b7bb7508b7f0fb</gtr:id><gtr:otherNames>Wang LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>56d706b8b93ec0.64808012</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9459C041-369D-4CCC-A1A6-FDD5D91A8590</gtr:id><gtr:title>Drug radiotherapy combinations: review of previous failures and reasons for future optimism.</gtr:title><gtr:parentPublicationTitle>Cancer treatment reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b510af5c8675372b5bf45633694ef94"><gtr:id>9b510af5c8675372b5bf45633694ef94</gtr:id><gtr:otherNames>Higgins GS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7372</gtr:issn><gtr:outcomeId>5655864e72e2d2.51186575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>040AB96A-1156-4D44-AB56-7A2390CE443F</gtr:id><gtr:title>The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.</gtr:title><gtr:parentPublicationTitle>Cancer biology &amp; therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/574aa5fbcc2eb8c8e59f4f4bda22d5c5"><gtr:id>574aa5fbcc2eb8c8e59f4f4bda22d5c5</gtr:id><gtr:otherNames>Prevo R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1538-4047</gtr:issn><gtr:outcomeId>pm_12478_28_22825331</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12004</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>